Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s).

2528 Background: A Phase 1b study (NCT02572687) was conducted to examine the combined effects of Ram (anti VEGFR2) and Durva (anti PD-L1). Methods: Patients (pts) with previously-treated, advanced NSCLC (Cohort [CH] A), G/GEJ adenocarcinoma (CH B), HCC (CH C), ECOG PS 0-1, and no prior Ram or IO therapy, received Ram (10 mg/kg) + Durva (1125 mg) Q3W (CH A) or Ram (8 mg/kg) + Durva (750 mg) Q2W (CH B, C). Primary objective was to assess safety; efficacy was also examined. PD-L1 expression of tumor cells (TC) +/- immune cells (IC) in pretreatment tumor biopsies were assessed using SP263 immunohistochemistry. “High” PD-L1 is ≥25% TC for NSCLC and ≥25% TC or IC for G/GEJ, HCC. Results: CH A, B and C enrolled pts with ECOG PS 1 (%) of 43, 66, 68; and average of 2, 2, 1 prior regimens, respectively. The most common grade 3/4 treatment-emergent adverse events (AE) are hypertension (HTN) (14.3, 17.2, 17.9%), anemia (3.6, 24.1, 21.4%), and fatigue (10.7, 10.3, 10.7%). Grade 3/4 AEs of special interest ( > 5% total pts) for Ram: HTN, bleeding events (3.6, 10.3, 10.7%), Venous thromboembolic events (0, 10.3, 7.1%); for Durva: increase in lipase (10.7, 3.4, 10.6%) and AST (3.6, 3.4, 17.9 %). Data from CH B,C suggest a trend toward increased efficacy in pts with high PD-L1 expressing tumors. Conclusions: Ram + Durva generated no unexpected toxicities and demonstrated antitumor activity. Results in pts with high PD-L1 HCC and G/GEJ cancer warrant further evaluation. Clinical trial information: NCT02572687. [Table: see text]

• Publication year

  2019

• Venue

  Journal of Clinical Oncology

• Publication date

  2019-05-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2019.37.15_SUPPL.2528
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Immunotherapy in GI Cancers: Lessons from Key Trials and Future Clinical Applications

  2025cites this paper
• Evaluation of Anti-Angiogenic Therapy Combined with Immunotherapy and Chemotherapy as a Strategy to Treat Locally Advanced and Metastatic Non-Small-Cell Lung Cancer

  2024cites this paper
• Sequencing Systemic Therapy in Hepatocellular Carcinoma

  2023influential citation
• Identification of Ferroptosis‐related molecular model and immune subtypes of hepatocellular carcinoma for individual therapy

  2022cites this paper
• Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial

  2021cites this paper
• Targeted and immunotherapy in the era of personalised gastric cancer treatment.

  2021cites this paper
• Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment

  2021cites this paper
• Innovative strategies in metastatic gastric cancer: a short review

  2021cites this paper
• New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer

  2021cites this paper
• Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma

  2021cites this paper
• Immune Checkpoint Inhibitors in the Treatment of HCC

  2021cites this paper
• Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions.

  2020cites this paper
• Molecular and immunological paradigms of hepatocellular carcinoma: Special reference to therapeutic approaches

  2020cites this paper
• PD-1 and PD-L1 inhibitors in oesophago-gastric cancers.

  2020cites this paper
• Esophageal, gastric cancer and immunotherapy: small steps in the right direction?

  2020influential citation
• Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.

  2020cites this paper
• Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma

  2020cites this paper
• Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy.

  2020cites this paper
• Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date

  2020cites this paper
• Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma

  2020cites this paper
• Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus

  2020cites this paper
• Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities

  2020cites this paper
• Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma.

  2020cites this paper
• Immune checkpoint inhibitors in gastrointestinal malignancies: what can we learn from experience with other tumors?

  2019cites this paper
• Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient Treated with a Novel Combination Treatment with Anti PDL1 Antibody (Durvalumab) and VEGFR2 Antibody (Ramucirumab)

  2019cites this paper